What is NOT a component of patient preparation for I-131 therapy for thyroid cancer?

In the context of I-131 therapy for thyroid cancer, administering oral potassium iodide is not a standard component of patient preparation. I-131 therapy is aimed at treating hyperthyroidism or thyroid cancer, and potassium iodide can actually affect the uptake of radioactive iodine by the thyroid gland. Its administration prior to I-131 therapy would interfere with the treatment by saturating the thyroid with stable iodine, reducing the effectiveness of the radioactive treatment.

On the other hand, ruling out pregnancy is critical because I-131 can have harmful effects on a developing fetus. Diet restrictions may be recommended prior to treatment to enhance the efficacy of the therapy by lowering the iodine levels in the body, which can help maximize the uptake of the radioactive iodine. Finally, reviewing isolation requirements is an important aspect of patient preparation, as patients will emit radiation following therapy and must understand how to minimize exposure to others during this period. Therefore, all these components are essential for patient safety and treatment efficacy, except for the administration of potassium iodide.